Current perspectives on the optimal management of infantile hemangioma

Infantile hemangiomas (IHs) are the most common benign tumor of infancy. As our understanding of their pathobiology has evolved, treatment has become more focused and tailored to specifically treat IH while minimizing adverse effects. Propranolol has gained FDA approval as the first medical therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Grzesik, Peter, Wu, June K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774589/
https://www.ncbi.nlm.nih.gov/pubmed/29388636
http://dx.doi.org/10.2147/PHMT.S115528
_version_ 1783293777356521472
author Grzesik, Peter
Wu, June K
author_facet Grzesik, Peter
Wu, June K
author_sort Grzesik, Peter
collection PubMed
description Infantile hemangiomas (IHs) are the most common benign tumor of infancy. As our understanding of their pathobiology has evolved, treatment has become more focused and tailored to specifically treat IH while minimizing adverse effects. Propranolol has gained FDA approval as the first medical therapy for a traditionally surgical disease. This review provides readers with an overview of IH, treatment modalities, and addresses specific considerations in IH disease management.
format Online
Article
Text
id pubmed-5774589
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57745892018-01-31 Current perspectives on the optimal management of infantile hemangioma Grzesik, Peter Wu, June K Pediatric Health Med Ther Review Infantile hemangiomas (IHs) are the most common benign tumor of infancy. As our understanding of their pathobiology has evolved, treatment has become more focused and tailored to specifically treat IH while minimizing adverse effects. Propranolol has gained FDA approval as the first medical therapy for a traditionally surgical disease. This review provides readers with an overview of IH, treatment modalities, and addresses specific considerations in IH disease management. Dove Medical Press 2017-12-06 /pmc/articles/PMC5774589/ /pubmed/29388636 http://dx.doi.org/10.2147/PHMT.S115528 Text en © 2017 Grzesik and Wu. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Grzesik, Peter
Wu, June K
Current perspectives on the optimal management of infantile hemangioma
title Current perspectives on the optimal management of infantile hemangioma
title_full Current perspectives on the optimal management of infantile hemangioma
title_fullStr Current perspectives on the optimal management of infantile hemangioma
title_full_unstemmed Current perspectives on the optimal management of infantile hemangioma
title_short Current perspectives on the optimal management of infantile hemangioma
title_sort current perspectives on the optimal management of infantile hemangioma
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5774589/
https://www.ncbi.nlm.nih.gov/pubmed/29388636
http://dx.doi.org/10.2147/PHMT.S115528
work_keys_str_mv AT grzesikpeter currentperspectivesontheoptimalmanagementofinfantilehemangioma
AT wujunek currentperspectivesontheoptimalmanagementofinfantilehemangioma

Ejemplares similares